Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for
diabetes. Previous retrospective studies have shown that these treatments induced an increase
in pancreatic mass with potentially a risk for pancreatitis and development of precancerous
lesions.
The aim of our study is to provide a better understanding of the pathophysiological
mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain
treatment of type 2 diabetes.
Phase:
N/A
Details
Lead Sponsor:
Erasme University Hospital
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Exenatide Liraglutide Lixisenatide